Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segm…

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven ...
Business Insider

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

TAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing ...
Yahoo Finance

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

TAMPA, Fla. and LONDON, April 27, 2026 (GLOBE NEWSWIRE)-- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing ...

Why Akari Therapeutics stock is falling on Tuesday

Akari Therapeutics PLC AKTX stock is experiencing a price correction on Tuesday. The decline follows an extraordinary 255% ...

Akari Therapeutics announces $5.5M private placement offering

Akari Therapeutics (AKTX) announced on Thursday the pricing of a private placement financing round, expecting to raise an aggregate of approximately $5.5M in gross proceeds. With these funds, the ...

Akari Therapeutics Plc: Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator ...
Mena FN

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection Of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

(MENAFN- GlobeNewsWire - Nasdaq) Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari's ...
manilatimes

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications TAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) ...